Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Modelling the role of enzymatic pathways in the metabolism of docosahexaenoic acid by monocytes and its association with osteoarthritic pain.

Mathematical biosciences·2024
Same author

Precision computerised cognitive behavioural therapy (cCBT) for adolescents with depression: a pilot and feasibility randomised controlled trial protocol for SPARX-UK.

Pilot and feasibility studies·2024
Same author

Easy to interpret coordinate based meta-analysis of neuroimaging studies: Analysis of brain coordinates (ABC).

Journal of neuroscience methods·2022
Same author

Beta interferons as immunotherapy in multiple sclerosis: a new outlook on a classic drug during the COVID-19 pandemic.

QJM : monthly journal of the Association of Physicians·2021
Same author

Lipidomic identification of plasma lipids associated with pain behaviour and pathology in a mouse model of osteoarthritis.

Metabolomics : Official journal of the Metabolomic Society·2020
Same author

Coordinate based meta-analysis of networks in neuroimaging studies.

NeuroImage·2019
Same journal

Subjective cognitive decline among U.S. Cancer survivors, 2017-2024: Prevalence, cancer-specific patterns, and associated factors.

Journal of the neurological sciences·2026
Same journal

Comment on "Comparative impact of mental and cardiovascular comorbidities on adverse outcomes in people with MS".

Journal of the neurological sciences·2026
Same journal

Comment on "Efficacy and safety of conventional immunosuppressant therapies in elderly patients with Neuromyelitis optica spectrum disorder: A target trial emulation study".

Journal of the neurological sciences·2026
Same journal

Increasing incidence of varicella-zoster virus meningitis in Japan, 2011-2022.

Journal of the neurological sciences·2026
Same journal

Comment on "Excellent agreement between automated deep learning-based and manual diffusion-weighted imaging infarct volume measurements in hyperacute stroke".

Journal of the neurological sciences·2026
Same journal

Shifting from alteplase to tenecteplase in acute ischemic stroke: Progress, promise, and perils.

Journal of the neurological sciences·2026
See all related articles

Related Experiment Video

Updated: Jun 20, 2026

Lipidomics and Transcriptomics in Neurological Diseases
09:58

Lipidomics and Transcriptomics in Neurological Diseases

Published on: March 18, 2022

Plasma endocannabinoid levels in multiple sclerosis.

L Jean-Gilles1, S Feng, C R Tench

  • 1Division of Clinical Neurology at Queens Medical Centre, University of Nottingham, Nottingham NG7 2UH, United Kingdom.

Journal of the Neurological Sciences
|August 22, 2009
PubMed
Summary
This summary is machine-generated.

The endocannabinoid (EC) system is altered in multiple sclerosis (MS), with specific compound levels varying by disease subtype. This suggests potential therapeutic targets for MS management.

More Related Videos

Oromucosal as an Alternative Method for Administration of Cannabis Products in Rodents
03:43

Oromucosal as an Alternative Method for Administration of Cannabis Products in Rodents

Published on: August 22, 2025

Synthesis of a Deuterated Standard for the Quantification of 2-Arachidonoylglycerol in Caenorhabditis elegans
14:25

Synthesis of a Deuterated Standard for the Quantification of 2-Arachidonoylglycerol in Caenorhabditis elegans

Published on: September 21, 2019

Related Experiment Videos

Last Updated: Jun 20, 2026

Lipidomics and Transcriptomics in Neurological Diseases
09:58

Lipidomics and Transcriptomics in Neurological Diseases

Published on: March 18, 2022

Oromucosal as an Alternative Method for Administration of Cannabis Products in Rodents
03:43

Oromucosal as an Alternative Method for Administration of Cannabis Products in Rodents

Published on: August 22, 2025

Synthesis of a Deuterated Standard for the Quantification of 2-Arachidonoylglycerol in Caenorhabditis elegans
14:25

Synthesis of a Deuterated Standard for the Quantification of 2-Arachidonoylglycerol in Caenorhabditis elegans

Published on: September 21, 2019

Area of Science:

  • Neuroscience
  • Immunology
  • Pharmacology

Background:

  • Multiple sclerosis (MS) is a chronic central nervous system inflammatory disease.
  • The endocannabinoid (EC) system plays a role in immunomodulation, symptom management, and neuroprotection.
  • Understanding EC system alterations in MS is crucial for developing novel therapies.

Purpose of the Study:

  • To investigate alterations in endocannabinoid (EC) and related compound levels in patients with multiple sclerosis (MS).
  • To explore potential correlations between EC system components and different MS subtypes.

Main Methods:

  • Plasma and whole blood samples were collected from 24 MS patients (relapsing-remitting, secondary-progressive, primary-progressive) and 17 controls.
  • Liquid chromatography-tandem mass spectrometry was used to quantify plasma ECs.
  • Quantitative reverse transcriptase-polymerase chain reaction measured mRNA levels of fatty acid amide hydrolase (FAAH) and cannabinoid receptors (CB1, CB2).

Main Results:

  • Anandamide (AEA) and palmitoylethanolamide (PEA) were elevated in relapsing-remitting MS (RRMS) and secondary-progressive MS (SPMS) patients compared to controls.
  • Oleoylethanolamide levels were also increased in SPMS.
  • FAAH mRNA was decreased in SPMS, while CB1 and CB2 mRNA were increased in primary-progressive MS (PPMS).

Conclusions:

  • The endocannabinoid (EC) system exhibits altered levels and gene expression in multiple sclerosis (MS).
  • These alterations may be specific to MS subtypes, indicating dynamic modulation.
  • Further research with larger patient cohorts is warranted to confirm these findings and explore therapeutic implications.